Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Validation for PDCs

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Mar 28, 2023 5:20pm

67 Views

Post# 35365552

RE:Validation for PDCs

If they announce a way forward with th1902 does it have to be with good old docetaxel or they can scrap that and start over with the other warhed. It's confusing to the onlooker. I'm confused beween the platform and the warhead... are they inseperable and considered one in th1902.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China